Medical Nutrition Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Oral and Enteral is the fastest growing sector, North America is the largest market

The global medical nutrition market is projected to expand significantly, rising from USD 63.91 billion in 2025 to USD 100.35 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.81%. This sector encompasses therapeutic products, such as enteral and parenteral formulations, alongside oral nutritional supplements, all developed to address the specific dietary needs of patients with various medical conditions under expert guidance. Key factors driving this market's growth are the increasing incidence of chronic diseases and a rapidly expanding elderly global population requiring specialized clinical dietary management. For instance, an estimated 1.3 million individuals over 65 in the UK were malnourished in 2025, according to the Malnutrition Task Force, highlighting the critical need for nutritional interventions in the geriatric population, which in turn fuels the demand for specialized products aimed at enhancing patient outcomes and recovery.

Nevertheless, the market faces considerable hurdles, primarily due to rigorous regulatory frameworks and intricate reimbursement systems. Producers frequently struggle with navigating varied legal requirements and obtaining adequate financial coverage for their offerings, which can impede the launch of new treatments. These regulatory and economic impediments have the potential to restrict patient accessibility and postpone the market introduction of vital nutritional solutions, thereby presenting a notable challenge to the overall expansion of the market.

Market Drivers

The increasing occurrence of chronic and metabolic disorders is a major impetus for the global medical nutrition market, driving a significant demand for dietary interventions tailored to specific diseases. With conditions like diabetes and cancer becoming more prevalent, healthcare professionals are increasingly turning to targeted nutritional therapies to manage symptoms and improve treatment effectiveness. This trend spurs the creation of specialized products, such as low-glycemic index options for blood sugar control and high-protein supplements for cancer patients to prevent muscle wasting. The urgency for integrated nutritional management is highlighted by the World Health Organization's 'World Health Statistics 2025' report from May 2025, which states that noncommunicable diseases are now responsible for most premature deaths globally among individuals under 70, thereby ensuring a continuous need for long-term therapeutic solutions.

Concurrently, the growing incidence of clinical malnutrition within hospitals is boosting market expansion, as healthcare institutions focus on nutritional care to lessen financial strains. Malnutrition among hospitalized patients is associated with slower recovery and longer hospital stays, leading administrators to implement stringent intervention protocols. According to resources from the American Society for Parenteral and Enteral Nutrition's 'Malnutrition Awareness Week 2025' in September 2025, untreated malnutrition can raise hospital costs by about 73% and considerably increase the chance of readmission. Consequently, manufacturers are observing strong demand for enteral and parenteral products designed for clinical recovery, as evidenced by Danone's 'Third Quarter 2025 Sales' press release in October 2025, which reported double-digit sales growth in its adult medical nutrition division, indicating a heightened reliance on therapeutic nutrition to alleviate clinical complications.

Market Challenges

The global medical nutrition market's growth is significantly hindered by stringent regulatory environments and complicated reimbursement systems. Producers are required to navigate highly fragmented legal standards, where product categorization differs substantially across regions, frequently blurring the distinction between pharmaceutical drugs and food supplements. This lack of regulatory uniformity elevates compliance expenditures and extends the duration needed to launch new therapeutic formulations, consequently delaying revenue generation and diminishing the motivation for innovation.

Moreover, unpredictable reimbursement policies directly impede market expansion by restricting patients' access to crucial products. Despite clinical validation, numerous nutritional therapies often do not receive consistent insurance coverage, rendering them financially inaccessible for both patients and healthcare providers. This economic gap prevents the market from fully leveraging the pressing need for malnutrition management. Data from the Medical Nutrition International Industry (MNI) indicates that in 2025, the economic burden of disease-related malnutrition in Europe was an estimated €170 billion annually. This substantial sum underscores how administrative and financial obstacles effectively prevent the broad adoption of essential nutritional interventions, leaving a vast potential market undeveloped and negatively impacting overall industry revenue.

Market Trends

The swift uptake of GLP-1 receptor agonists for managing weight is establishing a new segment within the medical nutrition sector, specifically targeting the preservation of lean muscle mass and adequate micronutrient intake during accelerated weight reduction. Since these medications notably curb appetite, patients frequently find it challenging to fulfill their daily nutritional needs, thereby fueling the demand for high-protein, low-volume oral nutritional supplements (ONS) formulated to combat sarcopenic obesity. Manufacturers are proactively adapting existing diabetes-specific products to address both glycemic control and muscle upkeep requirements. Abbott's 'Q4 Momentum Positions Abbott for Strong Growth in 2025' press release from January 2025 indicated a 7.2% sales increase in its Nutrition segment, largely propelled by strong demand for Glucerna and Ensure products supporting patients on GLP-1 therapies.

Simultaneously, the market is undergoing a significant transition towards plant-based enteral feeding formulas and supplements, spurred by consumer demand for allergen-free and environmentally friendly components. While the industry has traditionally relied on milk-protein formulations, there is a growing trend to integrate hydrolyzed pea and soy proteins to enhance gastrointestinal tolerance and align with the clean-label preferences common in the wider food and beverage industry. This development is prompting a reconfiguration of product portfolios, as leading companies acquire niche plant-based startups to attract this expanding demographic. As reported by Dairy Reporter in October 2025, Danone's Specialized Nutrition division, boosted by recent plant-based investments, contributed 33.5% to the company's total group sales during the first nine months of 2025.

Key Market Players

• Abbott Nutrition Ltd
• Nestle Health Science SA
• Baxter Healthcare Corp
• B Braun SE
• Danone SA
• Perrigo Co PLC
• Fresenius Kabi AG
• AYMES Nutrition
• Reckitt Benckiser Group PLC
• Ajinomoto Cambrooke Inc.

Report Scope

In this report, the Global Medical Nutrition Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Medical Nutrition Market, by Route of Administration:

• Oral and Enteral
• Parenteral

Medical Nutrition Market, by Application:

• Malnutrition
• Metabolic Disorders
• Gastrointestinal Diseases
• Cancer
• Neurological Diseases
• Others

Medical Nutrition Market, by End User:

• Pediatric
• Adult

Medical Nutrition Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Medical Nutrition Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.